SCHEMBL3801173

SCHEMBL3801173

COc1c(Cl)cccc1Nc1ncnc2scc(C)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.47
DYRK3 O43781 3/20 0.47
MAP4K4 O95819 3/20 0.47
PIM1 P11309 3/20 0.47
CLK2 P49760 3/20 0.47
IRAK1 P51617 3/20 0.47
CSNK2A1 P68400 3/20 0.47
MAP4K2 Q12851 3/20 0.47
DYRK1A Q13627 3/20 0.47
AURKB Q96GD4 3/20 0.47
CLK4 Q9HAZ1 3/20 0.47
HIPK4 Q8NE63 2/20 0.47
PIM3 Q86V86 2/20 0.47
MKNK2 Q9HBH9 2/20 0.47
SRPK1 Q96SB4 1/20 0.47
CSNK1G1 Q9HCP0 1/20 0.47
PIP4K2C Q8TBX8 2/20 0.46
LMNA P02545 5/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3805579 0.81 MAPT (0.53) EGFRDYRK3MAP4K4PIM1CLK2
SCHEMBL3801448 0.79 RAB9A (0.57) EGFRPIP4K2CGAARETRAB9A
SCHEMBL3798891 0.79 HTT (0.49) MKNK2PIP4K2CLMNAHTTRAB9A
SCHEMBL3799287 0.77 PIP4K2C (0.51) EGFRDYRK3MAP4K4PIM1CLK2
SCHEMBL3801214 0.75 PIP4K2C (0.47) EGFRDYRK3MAP4K4PIM1CLK2
SCHEMBL3799470 0.75 PIP4K2C (0.52) EGFRDYRK3MAP4K4PIM1CLK2
SCHEMBL3799687 0.75 PIP4K2C (0.52) EGFRDYRK3MAP4K4PIM1CLK2
SCHEMBL4603243 0.75 PIP4K2C (0.45) MKNK2PIP4K2CLMNAPOLBGAA
SCHEMBL3801425 0.74 PIP4K2C (0.51) EGFRDYRK3MAP4K4PIM1CLK2
SCHEMBL5463611 0.74 MAPT (0.62) PIP4K2CLMNAPOLBGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-06-10 US claimed
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2010-06-10 US disclosed
EP-1899353-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DeveloGen Aktiengesellschaft (DE) 2008-03-19 EP disclosed
WO-2007059905-A9 THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES DEVELOGEN AG (DE) 2007-11-01 WO disclosed
WO-2007059905-A2 THIENOPYRIMIDINES TREATING INFLAMMATORY DISEASES DEVELOGEN AKTIENGESELLSCHAFT (DE) 2007-05-31 WO disclosed
WO-2006136402-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143341-A1 THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS DTYMK, CMPK1, PDXK EGFR 3787/4885DYRK3 815/4885MAP4K4 160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.